Home > Boards > US Listed > Biotechs > Cellectar Biosciences Inc. (CLRB)

CLRB ASH Presentation 12/7/19 Abstract:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Crusader Member Profile
 
Followed By 91
Posts 5,746
Boards Moderated 0
Alias Born 06/05/08
160x600 placeholder
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 7/13/2020 2:38:51 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2020 4:16:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/6/2020 6:32:07 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/6/2020 6:30:18 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/1/2020 4:02:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:24:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:24:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:23:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:22:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:22:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2020 4:02:12 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/12/2020 4:19:04 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/12/2020 4:10:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2020 4:35:08 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/10/2020 6:33:36 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:12:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:09:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:09:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:08:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/5/2020 4:31:08 PM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 6/4/2020 6:03:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2020 9:15:54 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/3/2020 6:01:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/1/2020 8:31:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2020 8:15:53 AM
Crusader   Monday, 12/02/19 03:19:23 PM
Re: None
Post # of 7994 
CLRB ASH Presentation 12/7/19 Abstract:

As posted by ASH:

...Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Hematology Disease Topics & Pathways:
Adult, B-Cell Lymphoma, Technology and Procedures, Study Population, radiation
Saturday, December 7, 2019: 10:45 AM
Hall E1, Level 2 (Orange County Convention Center)
Sikander Ailawadhi, MD1, Patrick J. Stiff, MD2, Emad Ibrahim, MBBCh, MD3, Anusha Vallurupalli, MBBS4, Elizabeth H. Cull, MD5, Damian J. Green, MD6, Kate Oliver, BS7* and Jarrod Longcor8*

1Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL
2Loyola University Chicago Stritch School of Medicine, Maywood, IL
3Redlands Community Hospital, Redlands, CA
4University of Kansas Cancer Center, Westwood, KS
5Cancer Institute, Prisma Health, Piedmont, SC
6Fred Hutchinson Cancer Research Center, Seattle, WA
7Cellectar Biosciences, Madison, WI
8Cellectar Biosciences, Florham Park, NJ

Background: CLR 131 is a novel targeted radiotherapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Based on initial preclinical and clinical experience and the radiosensitivity of MM, fractionated dosing of CLR 131 is being examined in RRMM in a Phase 1 trial (NCT02278315) and a Phase 2 trial, CLOVER-1 (NCT02952508).
Methods: Both the Phase 1 and Phase 2 trials of CLR 131 aim to determine efficacy and safety in RRMM. Eligibility criteria include progressive or relapsed MM that is refractory to at least 1 proteasome inhibitor (PI) and 1 immunomodulatory (IMiD) drug with no upper limit to the number of prior lines of therapy. Prior autologous stem cell transplant (ASCT) and external beam radiation therapy are allowed (< 20% of total marrow irradiated). The Phase 1 trial was a single and fractionated ascending dose escalation safety study and the Phase 2 trial is evaluating 3 doses: a bolus dose and 2 fractionated doses. The fractionated doses of CLR 131 included infusion of either 31.25 mCi/m2 CLR 131 or 37.5 mCi/m2 CLR 131 (administered as 15.625 mCi/m2 or 18.75 mCi/m2, respectively, on day 1 and day 7 (± 1 day)) administered as a 30-minute intravenous infusion is reported here. Adverse events (AEs) are graded by NCI-CTCAE v4.03. Responses were determined using IMWG criteria as assessed by the investigator.

Results: As of 30Jul2019, 10 subjects have received fractionated 31.25 mCi/m2 and 6 subjects fractionated 37.5 mCi/m2 CLR 131. In addition, 1 subject was scheduled to receive fractionated 37.5 mCi/m2 CLR 131 but died due to progressive disease prior to administration of the second dose; this subject is not included in the analyses below as they did not receive both fractionated doses. There is no upper age limit for enrollment and the median age for the 16 RRMM patients was 71 (range 51-83), including 6 females and 10 males with a median of 4 prior therapies (range 2 to 13). Seven patients had prior ASCT.

CLR 131 demonstrated 100% disease control rate in subjects receiving either fractionated dose of CLR 131. The overall response rate (ORR) in the fractionated 37.5 mCi/m2 cohort is 50%. Three subjects in the cohort experienced a partial responses (PR), median time to response 43 days, and the other three had minimal responses (MR) with an average 39% reduction in m-protein. In this cohort, 80% of the subjects were either quad- or penta-refractory; all 80% were refractory to daratumumab. There were two subjects in the 31.25 mCi/m2 cohort with non-secretory disease and their status was followed by FDG-PET imaging. Both have been excluded from the evaluation of efficacy as their disease does not meet with IMWG criteria for response. No patients in this cohort achieved a PR or better however a majority of the subjects experienced a minimal response. The primary AEs include thrombocytopenia, anemia, neutropenia, and fatigue (Table 2). The hematologic AEs were expected, manageable and followed a predictable timeline to nadir (average. 40 days) and subsequent recovery (average 17 days post nadir).

Conclusions: CLR 131 is a unique, first in class targeted radiotherapeutic for RRMM. Preliminary data for CLR 131 administered as a fractionated dose shows an acceptable and expected safety profile in this patient population. Fractionated dosing at 37.5 mCi/m2 has shown an efficacy signal and has been adopted as the standard for CLR 131 dosing in ongoing and future trials. Dose escalation to determine the highest tolerated dose is ongoing in the Phase 1 study and is currently examining a fractionated infusion of 40 mCi/m2 administered as 20 mCi/m2 CLR 131 on day 1 and day 7 (± 1 day). [/] Based upon these data enrollment to the fractionated 37.5 mCi/m2 cohort of the Phase 2 trial continues...”


Link: https://ash.confex.com/ash/2019/webprogram/Paper131014.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist